LXY3  (Synonyms: LXY2)

LXY3 (LXY2) is a VLA-3-blocking peptide that inhibits the interaction between integrin α3β1 (VLA-3) on neutrophil surfaces and laminin in the basement membrane, thereby preventing neutrophil migration across the tumor vascular basement membrane barrier. LXY3 is used to block neutrophil-mediated nanoparticle release from perivascular pools into the tumor interstitium. LXY3 is commonly employed for targeted imaging of breast cancer^[1][2].

885.88

C₃₂H₄₃N₁₁O₁₅S₂

1095009-44-1

{d-Cys}-{d-Asp}-Gly-{Tyr(3-NO2)}-Gly-{Hyp}-Asn-{d-Cys}-NH2 (disulfide bridge: d-Cys1-d-Cys8)

{d-Cys}-{d-Asp}-G-{Tyr(3-NO2)}-G-{Hyp}-N-{d-Cys}-NH2 (disulfide bridge: d-Cys1-d-Cys8)

O=C1[C@]2(N(C[C@H](O)C2)C(CNC([C@H](CC3=CC([N+]([O-])=O)=C(O)C=C3)NC(CNC([C@@H](CC(O)=O)NC([C@H](N)CSSC[C@H](C(N)=O)NC([C@H](CC(N)=O)N1)=O)=O)=O)=O)=O)=O)[H]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wang Q, et al. Breaking through the basement membrane barrier to improve nanotherapeutic delivery to tumours. Nat Nanotechnol. 2024 Jan;19(1):95-105.  [Content Brief]

  [2]. Yao N. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J Med Chem. 2009 Jan 8;52(1):126-33.  [Content Brief]